Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.51 |
| ▸ | MMP3 | P08254 | 8/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758555 | 1.00 | MMP2 (0.51) | MMP2MMP3GRIK1 | |
| SCHEMBL7758431 | 0.82 | MMP2 (0.55) | MMP2MMP3GRIK1 | |
| SCHEMBL7319632 | 0.79 | GRIK1 (0.64) | MMP2MMP3GRIK1 | |
| SCHEMBL7427000 | 0.77 | MMP2 (0.53) | MMP2MMP3 | |
| SCHEMBL7763247 | 0.76 | MMP2 (0.52) | MMP2MMP3 | |
| SCHEMBL7763242 | 0.76 | MMP2 (0.52) | MMP2MMP3 | |
| SCHEMBL9574068 | 0.75 | MMP2 (0.57) | MMP2MMP3 | |
| SCHEMBL12162457 | 0.75 | MMP2 (0.57) | MMP2MMP3 | |
| SCHEMBL1026190 | 0.72 | GRIK1 (0.64) | MMP2MMP3GRIK1 | |
| SCHEMBL11743875 | 0.72 | GRIK1 (0.46) | MMP2MMP3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |